Navigation Links
Aratana Therapeutics Announces $20 Million Financing
Date:1/7/2011

KANSAS CITY, Kan., Jan. 7, 2011 /PRNewswire/ -- Aratana Therapeutics, a newly-formed company focused on the development of innovative therapies for the animal health industry, today announced that it has closed a $20 million Series A financing led by MPM Capital and Avalon Ventures.

"At Aratana, we will be focused on taking advancements from the human biopharmaceutical industry and applying them in new ways to treat and care for animals," said Dr. David Rosen, President and Founder of Aratana Therapeutics. "The addition of Dr. Linda Rhodes as CEO and the closing of the $20 million in financing are two major milestones that set Aratana up for future success moving forward."  

Dr. Linda Rhodes, a recognized leader in the fields of human and animal drug discovery and development, will join Aratana in February 2011 as Chief Executive Officer. Previously, Dr. Rhodes was founder and vice-president of clinical development at AlcheraBio, an entrepreneurial contract research organization devoted to helping major animal health companies develop new drugs.

"My entire career has been devoted to developing therapies for animals, and I am looking forward to continuing that work in this exciting, venture-capital model at Aratana," said Dr. Rhodes.

"Drs. Rhodes and Rosen are the perfect duo to execute the vision we have for Aratana," said Dr. Steven St. Peter, Managing Director at MPM Capital.  "Both are veterinarians, one with extensive drug development expertise and the other with extensive business development expertise."

Aratana's board of directors will include Dr. Rhodes; Dr. Steven St. Peter, Managing Director at MPM Capital; Jay Lichter, Managing Director at Avalon Ventures; and Ron Meeusen, Founder of Cultivian Ventures. Other investors in the round of financing include the Kansas Bioscience Authority.


'/>"/>
SOURCE Aratana Therapeutics
Copyright©2010 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
2. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
3. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
4. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
5. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
6. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
7. CV Therapeutics Receives European Approval for the Brand Name Ranexa(R)
8. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
9. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
10. Logical Therapeutics Inc. Announces Results of Phase 1b Clinical Study of its Naproxen Prodrug
11. Arno Therapeutics Announces Second Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2015)... (PRWEB) March 27, 2015 Earlier this ... the promotion of hair regrowth in adult men and ... I-II or Norwood Hamilton classifications of IIa-V and Fitzpatrick ... industry plagued by products that over-promise and under-deliver, FDA ... renewing faith and confidence among more than 80 million ...
(Date:3/27/2015)... , March 27, 2015   SurePure, Inc ... photopurification, announced today that the Company has completed ... continued trading of SurePure ("SURP") securities on OTCQB, ... for entrepreneurial and development stage companies. ... standards and eligibility requirements designed to improve marketplace ...
(Date:3/27/2015)... March 27, 2015  CASI Pharmaceuticals, Inc. (Nasdaq: ... development and commercialization of innovative therapeutics addressing cancer and ... a commercial focus on China , ... months ended December 31, 2014.  The ... ($0.05) per share, for the three months ended December ...
(Date:3/26/2015)... TORONTO , March 26, 2015 /PRNewswire/ - SQI ... SQIDF) announced that after dealing with certain matters, including ... of shareholders held on March 26, 2015 (the "Meeting") ... until April 8, 2015 at 11:00 a.m. ( ... Meeting has been changed from that previous disclosed. The ...
Breaking Biology Technology:Dr. Robert Leonard Applauds FDA Clearance of Capillus272Pro™ Hair Loss Laser Cap 2SurePure Completes Verification and Approved for Trading on the OTCQB Marketplace 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 2CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 3CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 4CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 5CASI Pharmaceuticals Reports 2014 Fourth Quarter And Full Year Financial Results 6SQI Diagnostics Inc. Announces Adjournment of Meeting 2
... Replikins Ltd. published a FluForecast(R) warning in April 7th, ... H1N1 cases. The company was able to state the ... Count(TM) genomics technology, which examines specific regions in virus ... 2008 announcement, attached below as published on the Web, ...
... cells to combat aging and help support healing , ... ... Aesthetics , a division of Histogen focused on providing unique, clinically ... launch of the ReGenica™ Rejuvenation System for anti-aging and post-resurfacing. ...
... Mass., April 27 LaVoie Group, a life science-focused ... selected as investor relations agency of record for Pegasus ... LaVoie Group, commented, "Pegasus has the opportunity to capture ... The Company is changing the standard of care in ...
Cached Biology Technology:Biotechnology Company, Replikins Ltd., Provided Advance Warning of Mexican H1N1 'Swine Flu' Virus Outbreak 2Biotechnology Company, Replikins Ltd., Provided Advance Warning of Mexican H1N1 'Swine Flu' Virus Outbreak 3Histogen Aesthetics Launches ReGenica Rejuvenation System 2Histogen Aesthetics Launches ReGenica Rejuvenation System 3Histogen Aesthetics Launches ReGenica Rejuvenation System 4LaVoie Group Adds Bio-Surgery Company, Pegasus Biologics, to Its Life Sciences Agency Roster 2
(Date:3/17/2015)... 17, 2015  MecklerMedia Corporation (OTCQX: MECK) announced ... service robots ever held in New ... May 11-13, 2015 at the Javits Convention Center. ... event include: Acorn Product Development; Axis NJ; c-Link ... Robotics; Littler; NewBotic Corporation; Neya Systems LLC; Reliabotics; ...
(Date:3/12/2015)... 12, 2015 Beta Systems ... and access management (IAM) solution for a fixed ... Beta System,s new IAM package, customers benefit from ... from multiple IAM implementations across different industries. The ... well as any necessary services and consulting. It ...
(Date:3/10/2015)...  Continuing its 167-year history of offering the Best, ... The Eye Scanning Password Authenticator , a device that ... websites or sensitive data. Employing the same ... the device has a small camera that scans and ... converting them into an encrypted ID that cannot be ...
Breaking Biology News(10 mins):MecklerMedia's RoboUniverse New York Announces Sponsors and Exhibitors, May 11-13, 2015 2Beta Systems Fast Forward IAM Available Now: a Standardized IAM Package at a Fixed Price 2Hammacher Schlemmer Introduces The Eye Scanning Password Authenticator 2
... burn crop residues and get the land ready for ... image from the MODIS instrument on the Aqua satellite. ... fires can be found at this URL: http://www.nasa.gov/mission_pages/fires/main/world/20130326-indochina.html ... the Moderate Resolution Imaging Spectroradiometer (MODIS) aboard the Aqua ...
... genes to living human tissue, the odds of success come ... used to bring new genetic material into a cell ... process will simplify non-viral transfection, providing a method researchers and ... deliver genes to cells. Developed by William Murphy, ...
... led by Dr. Suresh Alahari, Professor of Biochemistry and Molecular ... first to report that two specific tumor suppressor genes work ... tumor cells to the lungs. The research is published this ... Working in a mouse model, the LSUHSC research team studied ...
Cached Biology News:Material screening method allows more precise control over stem cells 2LSUHSC research discovers new drug target for metastatic breast cancer 2
Request Info...
Goat polyclonal to MLH3 Immunogen: Synthetic peptide: RQSLQQSMPPCEPP (Human) from C Terminus of the protein sequence according to NP_055196....
IRF7 Immunogen: Synthetic peptide corresponding to residues E(463) G T Q R E G V S S L D S S S(477) of human IRF7. Storage: -20 C, Avoid Freeze/Thaw Cycles...
Rabbit polyclonal to NMDAR1 e/f/g/h ( Abpromise for all tested applications)....
Biology Products: